Core Viewpoint - Anhui Wanbang Pharmaceutical Technology Co., Ltd. plans to use part of its raised funds to repurchase shares, with a total amount ranging from 15 million to 30 million yuan, aimed at employee stock ownership plans or equity incentive plans [1] Group 1 - The company will repurchase shares at a price not exceeding 60.62 yuan per share, which will be adjusted to a maximum of 60.27 yuan per share after the rights distribution on January 24, 2025 [1] - The company is required to disclose the progress of the repurchase within the first three trading days of each month [1] - The repurchase plan complies with relevant regulations and the company's own guidelines, including the Shenzhen Stock Exchange's self-regulatory guidelines [1] Group 2 - The company will execute the repurchase within a 12-month period from the date the board approved the plan, based on market conditions [1] - The company will fulfill its information disclosure obligations in a timely manner [1]

Group 1 - The company Wanbang Medical (301520.SZ) announced a share buyback program, having repurchased a total of 404,900 shares as of August 31, 2025, which represents 0.61% of the company's total share capital [1] - The highest transaction price during the buyback was 40.80 yuan per share, while the lowest was 34.56 yuan per share [1] - The total amount spent on the share buyback was 15.2334 million yuan, excluding transaction fees [1]

证券代码：301520 证券简称：万邦医药 公告编号：2025-052 安徽万邦医药科技股份有限公司 截至 2025 年 8 月 31 日，公司股份回购专用证券账户以集中竞价交易方式累 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日召开第二届董事会第十五次会议和第二届监事会第九次会议，审议通过了《关 于使用部分超募资金回购公司部分股份方案的议案》，同意公司使用超募资金以 集中竞价交易方式回购公司部分社会公众股股份并用于股权激励计划或员工持 股计划，用于回购股份的总金额为1,500万元-3,000万元，回购价格不超过60.62 元/股（含），具体回购股份的数量及金额以回购期满时实际回购的股份数量及金 额为准。本次回购的实施期限为董事会审议通过回购方案之日起 12 个月内。具 体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于使 用部分超募资金回购公司部分股份方案的公告》（公告编号：2024-040）和《回 购报告 ...

Group 1 - The stock price of Wanbang Medical is reported at 45.68 yuan, down 0.85 yuan or 1.83% from the previous trading day [1] - The company reached a maximum price of 46.44 yuan and a minimum of 45.64 yuan during the trading session, with a trading volume of 15,766 hands and a transaction amount of 73 million yuan [1] - Wanbang Medical's main business includes pharmaceutical research services and clinical research services, operating in the healthcare service industry [1] Group 2 - As of the first half of 2025, the company reported total assets of 1.592 billion yuan and net assets of 1.505 billion yuan [1] - The latest semi-annual report shows that the company achieved operating revenue of 147 million yuan, a year-on-year decrease of 21.57% [1] - The net profit attributable to the parent company was 26.81 million yuan, down 51.28% year-on-year, while the net profit after deducting non-recurring gains and losses was 12.33 million yuan, a decrease of 70.17% [1] Group 3 - The net cash flow from operating activities was 12.54 million yuan, a decline of 55.20% year-on-year [1] - The basic earnings per share for the reporting period were 0.4 yuan, with a weighted average return on equity of 1.79% [1] - On August 26, the net outflow of main funds from Wanbang Medical was 1.0683 million yuan, accounting for 0.1% of the circulating market value [1]

Group 1 - The report indicates that Minsheng Securities has effectively reviewed the information disclosure documents of Anhui Wanbang Pharmaceutical Technology Co., Ltd. with no instances of delayed reviews [1] - The company has established and effectively executed relevant regulations, including those to prevent related parties from occupying company resources and managing raised funds [1] - Minsheng Securities conducted monthly checks on the company's fundraising special accounts and confirmed that the progress of fundraising projects aligns with the disclosed information [1] Group 2 - The report states that there were no significant issues identified during the review process, and no measures were required to address any problems [1] - The company and its shareholders have fulfilled their commitments, with no reasons for non-compliance reported [2] - Training was conducted once on April 9, 2025, focusing on disclosure standards [1]

Core Insights - Wanbang Pharmaceutical (301520.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 147 million yuan, representing a year-on-year decrease of 21.57% [1] - The net profit attributable to shareholders was 26.81 million yuan, down 51.28% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses was 12.33 million yuan, reflecting a substantial decline of 70.17% year-on-year [1] - Basic earnings per share stood at 0.40 yuan [1]

根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》 的规定，将安徽万邦医药科技股份有限公司（以下简称"公司"）2025 年半年 度募集资金存放、管理与使用情况报告如下： 一、募集资金基本情况 安徽万邦医药科技股份有限公司 2025 年半年度募集资金存放、管理与使用情况的专项报告 截至 2025 年 6 月 30 日，公司累计使用募集资金 64,674.46 万元，扣除累计 已使用募集资金后，募集资金余额为 37,755.63 万元，募集资金专用账户利息收 入 2,585.40 万元，手续费支出 0.40 万元，股份回购手续费支出 0.16 万元，尚未 使用的回购专用证券账户余额利息收入 0.06 万元。截至 2025 年 6 月 30 日，尚 未使用的回购专用证券账户余额 26.56 万元，公司现金管理产品期末余额为 38,000.00 万元，受让大额存单前手收益 56.55 万元，募集资金专户余额为 2,257.43 万元。 （一）实际募集资金金额、资金到账时间 | 项目 | 金额（万元） | | --- | ...

安徽万邦医药科技股份有限公司 证券代码：301520 证券简称：万邦医药 公告编号：2025-051 关于使用部分闲置募集资金（含超募资金）及闲置自有资金 购买现金管理产品到期赎回并继续购买现金管理产品的进 展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"或"万邦医药"）于 2024 年 12 月 26 日召开第二届董事会第十六次会议、第二届监事会第十次会议，2025 年 1 月 15 日召开公司 2025 年第一次临时股东大会，审议通过了《关于调整自有 资金、闲置募集资金的现金管理额度及期限的议案》，同意公司将用于现金管理 的闲置自有资金额度调整至 7.2 亿元人民币（不超过），用于现金管理的募集资 金（含超募资金）调整至不超过人民币 3.8 亿元（含本数）及将募集资金专户余 额以协定存款方式存放，前述额度有效期为 2025 年第一次临时股东大会审议通 过之日起 12 个月，额度有效期内可循环滚动使用。保荐机构对此出具了无异议 的核查意见。 具 体 内 容 详 见 公 司 2024 年 12 月 31 日 ...

| 编制单位：安徽万邦医药科技股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2025年初占用资 | 2025年1-6月占用累计 | 2025年1-6月占用 | 2025年1-6月度偿 | 2025年6月末占用 | 占用形成原因 | 占用性质 | | | | 关联关系 | 会计科目 | 金余额 | 发生金额(不含利息) | 资金的利息 | 还累计发生金额 | 资金余额 | | | | 控股股东、实际控制人及 | 无 | | | | | | | - | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 小计 | — | — | — | - | - | - | - | - | | 非经营性占用 | | 前控股股东、实际控制人 | 无 | | | | | | | - | | 非经营性占用 | | 及其附属企业 | | | | | | | ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-048 安徽万邦医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 安徽万邦医药科技股份有限公司（以下简称"公司"）第三届董事会第二次 会议于 2025 年 8 月 25 日在公司 2 楼会议室以现场结合通讯表决的方式召开，会 议通知于 2025 年 8 月 22 日以通讯方式发出。会议应出席董事 5 人，实际出席董 事 5 人。其中许新珞先生、张洪斌先生、卓敏女士以通讯表决方式出席会议。会 议由董事长陶春蕾女士主持。公司高级管理人员列席了本次会议。本次会议的召 集、召开程序符合《中华人民共和国公司法》及《安徽万邦医药科技股份有限公 司章程》（以下简称"《公司章程》"）等有关规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《2025 年半年度报告及其摘要》 经审议，公司《2025 年半年度报告》全文及摘要的编制和审核程序符合法 律法规的相关规定；报告内容真实、准确、完整地反映了公司的实际情况，不存 在虚假记载、误导性陈述或重大遗漏。 具 体 ...